Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Research & Development: ¥391 Mil (TTM As of Mar. 2026)


SHSE:600566 Hubei Jumpcan Pharmaceutical Co Ltd SHSE:600566
87 GF Score
Price ¥22.44
GF Value ¥20.92
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Hubei Jumpcan Pharmaceutical Co Research & Development?

Hubei Jumpcan Pharmaceutical Co SHSE:600566 -0.09% 87 Research & Development is ¥391 Mil as of Mar. 2026. GuruFocus rates SHSE:600566 with a GF Score™ of 87/100 and a GF Value™ of ¥20.92 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hubei Jumpcan Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥107 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥391 Mil.

Hubei Jumpcan Pharmaceutical Co  (SHSE:600566) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hubei Jumpcan Pharmaceutical Co Research & Development Related Terms

Hubei Jumpcan Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hubei Jumpcan Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Jumpcan Pharmaceutical Co Research & Development Chart

Hubei Jumpcan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 523.44 553.30 464.40 444.78 385.10

Hubei Jumpcan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.95 88.95 81.96 113.25 106.83
SHSE:600566
87GF Score
Hubei Jumpcan Pharmaceutical Co Ltd SHSE:600566
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hubei Jumpcan Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥391 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥391 Mil mean?
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a Research & Development of ¥391 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors.
Is Hubei Jumpcan Pharmaceutical Co's Research & Development too high?
Hubei Jumpcan Pharmaceutical Co's current Research & Development is ¥391 Mil. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Hubei Jumpcan Pharmaceutical Co's Research & Development of ¥391 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. Hubei Jumpcan Pharmaceutical Co's current Research & Development is ¥391 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.92, compared to a current price of ¥22.44 — trading 7.3% above its estimated fair value. The current Research & Development is ¥391 Mil. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current Research & Development is ¥391 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?

Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥22.44 is trading 7.3% above its estimated GF Value™ of ¥20.92. GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600566:

  • Research & Development: ¥391 Mil
  • GF Value™: ¥20.92 vs. price of ¥22.44 (7.3% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hubei Jumpcan Pharmaceutical Co Business Description

Address Daqing West Road, Baota Bay, Jiangsu Province, Taixing, CHN, 225441
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
87GF Score

Get the complete analysis for SHSE:600566

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥22.44
Price
¥20.92
GF Value